Semax Research Spray — 10MG/10ML
Semax is a synthetic heptapeptide first developed in Russia in the late 1980s as a structural analog of the ACTH(4-10) fragment of adrenocorticotropic hormone. Its interaction with neurotrophic signaling pathways has made it one of the more extensively studied peptides.
Each bottle ships with 10mg of Semax formulated in a research spray delivery format, sealed for research use, backed by Phantom Peptides’ internal verification standard: independent third-party lab analysis.
Product Specifications
- Compound: Semax
- Class: Synthetic ACTH(4-10) analog heptapeptide
- Sequence: Met-Glu-His-Phe-Pro-Gly-Pro
- Molecular Weight: ~813.9 Da
- Form: Research spray (liquid solution)
- Bottle Size: 10mg per bottle
Research Background
The existing literature on Semax spans a handful of distinct research threads:
- Neurotrophin research: cell and animal model studies examining Semax’s role in stimulating brain-derived neurotrophic factor (BDNF) expression
- Neuroprotection research: studies on Semax’s effects in models of cerebral ischemia, stroke, and oxidative neuronal stress
- Cognitive and memory research: rodent studies examining learning, memory formation, and cognitive performance
- ACTH/melanocortin pathway research: biochemical studies on Semax’s structural relationship to ACTH(4-10) and downstream receptor signaling
- Behavioral and stress-response research: animal models examining anxiety-related behavior and stress reactivity
- Comparative neuropeptide research: Semax examined alongside other ACTH-derived and nootropic peptides in comparative cell and animal studies
Semax was developed through ACTH-fragment research, with the deepest body of published work coming out of Russian and Eastern European neuroscience and pharmacology research groups. For primary sources, PubMed (pubmed.ncbi.nlm.nih.gov) and NIH’s PMC database (pmc.ncbi.nlm.nih.gov) index the peer reviewed literature on Semax and related neuropeptide research.
